Latest revenue
$1.3M
as of 2026-03-31
Latest net income
$-618.5K
as of 2026-03-31
Net margin
-47.5%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AURX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $56.2M
- Enterprise value
- $56.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $3.23
- 52-wk low
- $0.84
- Beta
- —
- Shares out
- 48.4M
5-year trend
What this company does
ITEM 1. Business Corporate Overview Nuo Therapeutics, Inc. is a Delaware corporation organized in 1998 under the name Informatix Holdings, Inc. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In 2000, Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In 2001, Cytomedix, filed for bankruptcy, from which it emerged in 2002 under a Plan of Reorganization. In September 2007, Cytomedix received Section 510(k) clearance from the U. S. Food and Drug Administration (“FDA”) for the AutoloGel™ System, now known as the…
AI summary unavailable — showing raw filing excerpt
Generated from AURX's filing dated 2026-03-30
Key risks
ITEM 1A. Risk Factors An investment in the Company involves a high degree of risk. Before making an investment decision with respect to our common stock, you should consider the risks described below in addition to the cautionary statements and risks described elsewhere and the other information in this Annual Report and in our other filings with the SEC, including subsequent reports on Forms 10-Q and 8-K. The risks described below may not be the only risks the Company faces. Additional risks not yet known or currently believed to be immaterial may also impair our business. If any of these known or unknown risks or uncertainties actually occurs, our business, financial condition or results…
AI summary unavailable — showing raw filing excerpt
Generated from AURX's filing dated 2026-03-30
Profitability
Gross margin
66.9%
14.0%Operating margin
-76.0%
57.8%Net margin
-75.8%
55.5%Return on equity
-489.0%
8.1%Return on assets
-136.1%
30.3%Leverage
Debt / equity
2.59×
97.1%Long-term debt / equity
0.97×
Debt / assets
72.2%
27.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.3M | +168.8% | $-618.5K | +17.1% | -47.5% |
Q4 2025 2025-12-31 | $1.1M | +177.8% | $-578.5K | -16.5% | -52.7% |
Q3 2025 2025-09-30 | $1.0M | +178.2% | $-537.9K | +7.0% | -52.1% |
Q2 2025 2025-06-30 | $700.2K | +92.0% | $-649.7K | -20.3% | -92.8% |
Q1 2025 2025-03-31 | $484.4K | +106.5% | $-746.1K | -5.3% | -154.0% |
Q4 2024 2024-12-31 | $394.9K | — | $-496.7K | — | -125.8% |
Q3 2024 2024-09-30 | $371.0K | +59.7% | $-578.2K | +26.9% | -155.9% |
Q2 2024 2024-06-30 | $364.8K | +208.7% | $-540.1K | +38.1% | -148.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on AURX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$200.0K
Insider selling
$300.0K
Net activity
−$100.0K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2025-11-28 | David Emerson Jorden CEO/CFO | Sale | 200,000 | $1.50 | $300.0K | |
| 2025-07-30 | Charles E Sheedy 10%+ owner | Purchase | 133,333 | $1.50 | $200.0K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AURX
No institutional holdings on file for AURX yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once AURX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.